Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients

2013 ◽  
pp. 513-522 ◽  
Author(s):  
Eiji Kiyohara ◽  
Keisuke Hata ◽  
Stella Lam ◽  
Dave S. B. Hoon
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cutaneous Melanoma ◽  
Prognostic Biomarkers ◽  
Melanoma Patients

scholarly journals High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China

2018 ◽  
Vol 24 ◽  
pp. 324-331 ◽  
Author(s):  
Jisen Li ◽  
Wenhua Fu ◽  
Wei Zhang ◽  
Peng Li
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cutaneous Melanoma ◽  
Poor Survival ◽  
Melanoma Patients

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma

2004 ◽  
Vol 111 (5) ◽  
pp. 741-745 ◽  
Author(s):  
Simone Mocellin ◽  
Paolo Del Fiore ◽  
Laura Guarnieri ◽  
Romano Scalerta ◽  
Mirto Foletto ◽  
...  
Keyword(s):  
High Risk ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cutaneous Melanoma ◽  
Molecular Detection ◽  
Independent Prognostic Factor

scholarly journals Circulating Tumor Cells in Cutaneous Melanoma

2011 ◽  
Vol 131 (8) ◽  
pp. 1776-1777 ◽  
Author(s):  
Vincenzo De Giorgi ◽  
Pamela Pinzani ◽  
Francesca Salvianti ◽  
Marta Grazzini ◽  
Claudio Orlando ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cutaneous Melanoma

Abstract 584: Circulating tumor cells as prognostic biomarkers in glioblastoma

2021 ◽  
Author(s):  
Juliana Müller Bark ◽  
Arutha Kulasinghe ◽  
Paul Leo ◽  
Gunter Hartel ◽  
Majid E. Warkiani ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prognostic Biomarkers

scholarly journals Circulating Tumor Cells in Melanoma Patients

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e41052 ◽  
Author(s):  
Gary A. Clawson ◽  
Eric Kimchi ◽  
Susan D. Patrick ◽  
Ping Xin ◽  
Ramdane Harouaka ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Melanoma Patients

scholarly journals Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients

2013 ◽  
Vol 133 (5) ◽  
pp. 1378-1381 ◽  
Author(s):  
Véronique Hofman ◽  
Marius Ilie ◽  
Elodie Long-Mira ◽  
Damien Giacchero ◽  
Catherine Butori ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Brafv600e Mutation ◽  
Melanoma Patients

Circulating Tumor Cells in Stage IV Melanoma Patients

2018 ◽  
Vol 227 (1) ◽  
pp. 116-124 ◽  
Author(s):  
Carolyn S. Hall ◽  
Merrick Ross ◽  
Jessica B. Bowman Bauldry ◽  
Joshua Upshaw ◽  
Mandar G. Karhade ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Stage Iv ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

scholarly journals Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy

2019 ◽  
Vol 66 (1) ◽  
pp. 169-177 ◽  
Author(s):  
Selena Y Lin ◽  
Shu-Ching Chang ◽  
Stella Lam ◽  
Romela Irene Ramos ◽  
Kevin Tran ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Tumor Cells ◽  
Clinical Outcomes ◽  
Circulating Tumor Cells ◽  
Progressive Disease ◽  
Molecular Profiling ◽  
Braf V600e ◽  
Blood Samples ◽  
Mrna Profiling ◽  
Melanoma Patients

Abstract BACKGROUND Blood molecular profiling of circulating tumor cells (CTCs) can enable monitoring of patients with metastatic melanoma during checkpoint inhibitor immunotherapy (CII) and in combination with targeted therapies. We developed a microfluidics-based CTC platform to explore CTC profiling utility in CII-treated patients with melanoma using a melanoma messenger RNA (mRNA)/DNA biomarker panel. METHODS Blood samples (n = 213) were collected prospectively from 75 American Joint Committee on Cancer-staged III/IV melanoma patients during CII treatment and those enriched for CTCs. CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF V600E DNA mutation. CTC biomarker status associations with clinical outcomes were assessed. RESULTS CTCs were detected in 88% of blood samples from patients with melanoma. CTC-derived biomarkers and clinical variables analyzed using classification and regression tree analysis revealed that a combination of lactate dehydrogenase, CTC-mRNA biomarkers, and tumor BRAF–mutation status was indicative of clinical outcomes for patients with stage IV melanoma (n = 52). The panel stratified low-risk and high-risk patients, whereby the latter had poor disease-free (P = 0.03) and overall survival (P = 0.02). Incorporation of a DNA biomarker with mRNA profiling increased overall CTC-detection capability by 57% compared to mRNA profiling only. RNA sequencing of isolated CTCs identified significant catenin beta 1 (CTNNB1) overexpression (P <0.01) compared to nondisease donor blood. CTC-CTNNB1 was associated with progressive disease/stable disease compared to complete-responder patient status (P = 0.02). Serial CTC profiling identified subclinical disease in patients who developed progressive disease during treatment/follow-up. CONCLUSIONS CTC-derived mRNA/DNA biomarkers have utility for monitoring CII, targeted, and combinatorial therapies in metastatic melanoma patients.

scholarly journals Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Pawel Mach ◽  
Rainer Kimmig ◽  
Sabine Kasimir-Bauer ◽  
Paul Buderath
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Survival Data ◽  
Liquid Biopsy ◽  
Therapy Response ◽  
Predictive Biomarkers ◽  
Prognostic Biomarkers ◽  
Immune Checkpoints

IntroductionEpithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy worldwide. Reliable predictive biomarkers are urgently needed to estimate the risk of relapse and to improve treatment management. Soluble immune-checkpoints in EOC are promising molecules serving as prognostic biomarkers accessible via liquid biopsy. We thus, aimed at elucidating the role of sB7-H4 in EOC.Material and MethodsWe analyzed soluble serum B7-H4 (sB7-H4) using ELISA and circulating tumor cells (CTCs) in blood applying the AdnaTest OvarianCancer in 85 patients suffering from advanced EOC. Findings were correlated with clinical parameters as well as survival data.ResultssB7-H4 was detectable in 14.1% patients, CTCs in 32.9% patients and simultaneous presence of CTCs and sB7-H4 was found in 7% patients, respectively. Although no association between sB7-H4 and CTC could be documented, each of them served as independent predictive factors for overall survival (OS).ConclusionsB7-H4 and CTCs are independent prognostic biomarkers for impaired survival in EOC. As they are easily accessible via liquid biopsy, they may be of potential benefit for the prediction of therapy response and survival for EOC patients.

Sign in / Sign up

Export Citation Format

Share Document